Abbvie Inc
ABBV - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$522.27B
Close$
Earnings Call Q3 2026
October 30, 2026 - AI Summary
Q3 2026 results: strong beat + rising outlook
- Adjusted EPS: $3.82, $0.07 above guidance midpoint (includes ~$0.11 unfavorable impact from acquired in-process R&D).
- Net revenues: $17.4B, ~10.5% operational growth (and ~$200M above expectations).
- Margin/expense posture: Adjusted gross margin 85.1%, adjusted R&D 13.9% of sales, adjusted SG&A 21.2%; adjusted operating margin 48.7% (also impacted by acquired IPR&D).
- Key message: AbbVie frames this as “top-tier sales and earnings growth” with continued momentum and confidence to raise full-year guidance.
2026 full-year guidance raised + specific revenue/product assumptions
- Adjusted EPS guidance (full year): raised by $0.11 at midpoint to $13.95–$13.99.
- Full-year net revenue: raised by $200M to ~$67.8B (with ~0.5% favorable FX assumed).
- Immunology guidance: $34.9B total; assumes Skyrizi ~$21.8B and Rinvoq ~$10.3B (both increased).
- Neuroscience guidance: $13.0B total (up +$300M), driven by Vraylar ~$4.2B, Botox Therapeutic ~$4.2B, oral CGRP ~$3.1B.
- Oncology guidance: $6.6B total (raised), reflecting higher Venclexta (~$3.1B) and lower Imbruvica (~$2.1B).
- Aesthetics guidance: ~$5.0B unchanged; assumes higher Botox Cosmetic (~$2.8B) offset by lower aesthetics revenues elsewhere.
Dividend: increase + capital returns (no buyback mentioned)
- Quarterly cash dividend increased by 5.2% to $1.82 per share, payable starting Feb 2027.
- AbbVie noted dividend growth since inception >350%.
- Free cash flow: generated ~$14B in first 9 months of 2026, supporting dividend and continued business development.
- Leverage: after the recent Apogee transaction, company expects ~2x net leverage within 2–3 years.
Exclusive for Stockcircle Pro members
Sign up
$168.69
42.8% downside
Current Fair Value
42.8% downsideOvervalued by 42.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $522.27 Billion |
|---|---|
| Enterprise Value | $586.52 Billion |
| Annual dividend | $6.92 |
| Dividend yield | 2.35% |
| Earnings per Share | $2.37 |
| Beta | 0.28 |
| Outstanding Shares | 1,770,992,000 |
Return
| Return on Equity | -106.49% |
|---|---|
| Return on Assets | 4.68% |
| Return on Invested Capital | 17.29% |
Valuation & Multiples
| P/E Ratio | 83.08 |
|---|---|
| PEG | 29.07 |
| Price to Sales | 8.19 |
| Price to Book Ratio | -73.73 |
| Enterprise Value to Revenue | 9.11 |
| Enterprise Value to EBIT | 36.29 |
| Enterprise Value to Net Income | 92 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | -11.93 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 30, 2026
EPS Estimate
$3.73
Consensus analyst estimateRevenue Estimate
$17.32 B
Consensus analyst estimateNext Earnings Call
Expected Date
February 3, 2027
EPS Estimate
$3.90
Consensus analyst estimateRevenue Estimate
$18.33 B
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.32, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.3212▼ 61.99% |
|---|---|
| Total Calls | 30,506▼ 99.75% |
| Total Puts | 9,800▼ 99.91% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.28%▼ 71.79% |
|---|---|
| Total Invested | $19.82B▼ 94.15% |
| Investors Holding | 2,015▼ 2338.00% |
About Abbvie Inc
57,000 employees
CEO: Richard Gonzalez
AbbVie Inc. operates as a global pharmaceutical enterprise, concentrating on the discovery, development, production, and commercialization of medicinal products across the world. Its extensive product portfolio addresses various therapeu...